BCLC 2025 Update: New Liver Cancer Staging, CUSE Framework, and Treatment Algorithm
The Barcelona Clinic Liver Cancer 2025 update introduces personalized decision-making, the CUSE framework, and treatment stage migration — transforming how hepatocellular carcinoma is managed worldwide.
What Is BCLC 2025?
The BCLC 2025 update marks an important step forward in liver cancer care. It preserves the familiar stage-based structure of the Barcelona Clinic Liver Cancer system while adding a more personalized and human approach to decision-making through the CUSE framework. For patients with hepatocellular carcinoma, this means treatment planning is no longer based on stage alone — liver function, treatment goals, patient preferences, and real-world feasibility now play a larger role in choosing the best path.
Key Innovations in BCLC 2025:
- CUSE Framework for complex, shared decision-making
- Refined patient selection using ALBI score, MELD, and Child-Pugh
- Official recognition of Treatment Stage Migration
- Immunotherapy combinations as first-line standard in BCLC C
- Enhanced bridging and downstaging protocols before liver transplant
Why This Update Matters
The 2025 update keeps the BCLC model simple enough to use in daily practice, but it is more flexible than previous versions. It recognizes that some patients benefit from treatment migration, meaning they may move to a different stage-based treatment pathway after response or progression. A major addition is the CUSE framework, which helps multidisciplinary teams handle complexity, uncertainty, subjectivity, and emotional factors in a structured way.
BCLC 2025 Staging and First-Line Treatments
In BCLC 2025, early-stage disease continues to focus on curative options such as resection, ablation, or transplant in selected patients. Intermediate-stage disease generally remains centered on locoregional therapy, while advanced-stage disease increasingly relies on immunotherapy-based systemic treatment. For end-stage disease, the emphasis remains on best supportive care.
BCLC 2025 Treatment Algorithm
Source: Reig et al., J Hepatol 2025 | The complete BCLC 2025 staging and treatment flow chart
| BCLC Stage | Key Features | First-Line Treatment | Expected Survival |
|---|---|---|---|
| BCLC 0 Very Early | Single ≤2 cm, preserved liver function, PS 0 | Ablation / Resection | > 5 years |
| BCLC A Early | Single or ≤3 nodules ≤3 cm, preserved liver function, PS 0 | Resection / Ablation / Transplant | > 5 years |
| BCLC B Intermediate | >3 nodules or up to 3 nodules with at least 1 >3 cm, preserved liver function, PS 0 | TACE | > 2.5 years |
| BCLC C Advanced | Vascular invasion and/or extrahepatic spread, any intrahepatic burden, preserved liver function, PS 0–2 | Combination Immunotherapy | > 2 years |
| BCLC D End-Stage | Any tumor burden, end-stage liver function, PS 3–4 | Best Supportive Care | < 1 year |
New First-Line Immunotherapy Regimens (BCLC C — Standard of Care):
- Atezolizumab + Bevacizumab
- Tremelimumab + Durvalumab
- Camrelizumab + Rivoceranib
- Ipilimumab + Nivolumab
Post-first-line options: Regorafenib, Cabozantinib, Ramucirumab (AFP ≥400 ng/mL), or clinical trials.
CUSE Framework Explained
For the first time, a global guideline formally acknowledges that medicine is not just science — it's human. The CUSE framework transforms uncertainty into a structured, iterative dialogue among tumor boards, clinicians, and patients.
CUSE is especially important because liver cancer care is not always a simple yes-or-no decision. Some patients have overlapping liver disease, borderline liver reserve, prior treatment failure, or strong personal preferences that affect the final plan.
What are we trying to achieve? Survival extension? Tumor control? Quality of life improvement? Palliation? This phase establishes clear, patient-specific treatment objectives.
Evaluate all available treatment pathways based on evidence strength, technical feasibility, resource availability, and risk-benefit profiles. Consider both conventional and emerging therapies.
Integrate patient preferences, personal values, cultural considerations, logistical constraints, and quality of life priorities into the decision-making process.
Implement the chosen strategy with built-in reassessment points. Adapt the approach based on treatment response, side effects, changing patient circumstances, or emerging new data.
CUSE = Decision-making that is shared, dynamic, and deeply human.
Treatment Stage Migration in HCC
BCLC 2025 officially recognizes and provides guidance for treatment stage migration — moving patients between stages based on treatment response or failure. This is one of the most practical innovations in the update, as real-world patients often do not fit neatly into a single stage over time.
Clinical Examples of Treatment Migration:
- Downstaging to Transplant: Successful TACE → tumor shrinkage → liver transplant eligibility
- TACE Failure → Systemic Therapy: BCLC B → BCLC C migration when locoregional treatment fails
- Immunotherapy Response → Local Consolidation: BCLC C → BCLC B migration after systemic therapy response
- Portal Vein Thrombosis → TARE Instead of TACE: Alternative locoregional approach based on vascular involvement
"Alternative sequences upon major response or failure may be considered according to CUSE framework but have not been robustly proven." — BCLC 2025
Is BCLC 2025 Relevant for International Patients?
For international patients, BCLC 2025 creates a useful shared language between hospitals, tumor boards, and referring teams. It also makes it easier to explain why one patient may be a candidate for transplant, another for TACE, and another for immunotherapy.
If you are seeking a second opinion or medical tourism support, a BCLC-based review can help organize the case before treatment planning begins. The framework provides:
- Standardized assessment that translates across healthcare systems
- Clear documentation of treatment rationale and alternatives
- Structured follow-up protocols for continuity of care
- Shared decision-making tools that account for cultural differences
Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update. J Hepatol. Published online October 26, 2025. doi:10.1016/j.jhep.2025.10.015
Frequently Asked Questions
BCLC 2025 is the latest update to the Barcelona Clinic Liver Cancer strategy for hepatocellular carcinoma. It keeps the stage-based structure but adds more individualized decision-making and the CUSE framework.
CUSE stands for Complexity, Uncertainty, Subjectivity, and Emotion. It helps doctors and patients make shared treatment decisions when the situation is not straightforward.
The update emphasizes personalized care, clearer clinical decision-making, treatment stage migration, and modern first-line treatment choices for advanced HCC.
Yes, the BCLC system is designed for hepatocellular carcinoma, which is the most common primary liver cancer.
Treatment stage migration means moving a patient to a different treatment pathway based on response, failure, or changing clinical conditions. For example, downstaging may make transplant possible, or progression after TACE may lead to systemic therapy.
Immunotherapy-based regimens are first-line options in advanced disease, with regimens such as atezolizumab-bevacizumab and durvalumab-tremelimumab widely discussed in updated HCC guidance.
Yes, the 2025 update supports treatment stage migration when response or clinical changes justify reassessment.
Because it gives a structured language for treatment review, tumor board discussion, and cross-border second opinions, which is especially useful in medical tourism.
No. BCLC is a major framework, but actual decisions should also consider liver function, comorbidities, tumor biology, patient goals, and multidisciplinary review.
A clinician needs your imaging, pathology if available, liver function tests, and overall clinical history to determine the appropriate stage and treatment path.
Need a Personalized Treatment Review Based on BCLC 2025?
Our team can help assess your case, review imaging and reports, and guide you toward the most appropriate next step — free of charge.
Submit Your Case for Review